Usefulness of [123I]metaiodobenzylguanidine ([123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies.
OBJECTIVE
To confirm the clinical usefulness of [123I] metaiodobenzylguanidine ([123I]MIBG) myocardial scintigraphy in the antemortem differential diagnosis between patients with Alzheimer's disease (AD) and those with dementia with Lewy bodies (DLB).


METHODS
We compared cardiac [123I] MIBG uptake in 10 patients with AD with that in 10 patients with DLB. We selected the patients with AD or DLB by using stringent diagnostic criteria that combined commonly used clinical criteria with tau protein levels in cerebrospinal fluid and radiographical examinations.


RESULTS
The heart to mediastinum ratio of [123I]MIBG uptake in all the patients with DLB was significantly lower than that in the patients with AD (p<0.01).


CONCLUSIONS
This study confirms that [123I]MIBG myocardial scintigraphy is useful in the antemortem differential diagnosis of AD and DLB.
Oide
Takashi
T
Third Department of Medicine, Shinshu University School of Medicine, Matsumoto.
Tokuda
Takahiko
T
Momose
Mitsuhiro
M
Oguchi
Kazuhiro
K
Nakamura
Akinori
A
Ohara
Shinji
S
Ikeda
Shu-ichi
S
D019797:3-Iodobenzylguanidine; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000000981:diagnostic imaging*; D003704:Dementia / Q000134:cerebrospinal fluid / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D006321:Heart / Q000000981:diagnostic imaging; D006801:Humans; D016631:Lewy Bodies / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019275:Radiopharmaceuticals; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods*; D016875:tau Proteins / Q000134:cerebrospinal fluid
D019275:Radiopharmaceuticals; D016875:tau Proteins; D019797:3-Iodobenzylguanidine